Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a
bioequivalent generic version of PLAVIX®, in the U.S. market
on May 18, 2012. The ANDAs for Clopidogrel Tablets USP, 75 mg
& 300 mg are approved by the United States Food & Drug
Administration (USFDA). Dr. Reddy's Laboratories was among the first
applicants to submit a substantially complete ANDA for Clopidogrel
Tablets USP, 300 mg with a Paragraph IV certification, and was awarded
180 days of marketing exclusivity for this strength.
The PLAVIX® brand had U.S. sales of approximately $6.740
billion for the most recent twelve months ending March 2012 according to
IMS Health.
Dr. Reddy's Clopidogrel Tablets USP, 75 mg are available in bottle count
sizes of 30, 90 and 500, and Clopidogrel Tablets USP, 300 mg are
available in blister packs of 30's count.